Alexander Martinko
Seminars
Wednesday 24th June 2026
Panel Discussion: Translating Mechanistic Insights into Effector Durability through Mitigating T-Cell Exhaustion
2:30 pm
- Analyzing whether mass changes in peripheral T-cell capacity serve as a predictive biomarker for clinical response are a signature of therapeutic failure
- Identifying points where TCEs fail to maintain sustained cytotoxic pressure and harnessing these insights to inform the timing of TCE administration
- Understanding how chronic antigen exposure under TCE stimulation drives effector dysfunction and how these findings can be used to engineer more resilient T-cell therapies
Wednesday 24th June 2026
Leveraging Single-Cell Sequencing to Identify Highly Precise Single and Combination T-Cell Engager Targets
2:00 pm
- Highlighting the central challenge in solid tumor T-cell engagers: identifying clean targets with high tumor specificity
- Cartography’s ATLAS platform: applying single-cell RNA sequencing to map tumor antigen expression and identify tumor-restricted antigens with broad patient coverage
- Discovery and advancement of CBI-1214, a T-cell engager targeting LY6G6D, a highly tumor-restricted colorectal cancer antigen entering the clinic in early 2026
- Extending this framework to multi-specific and AND-gated T-cell engagers through the SUMMIT platform, enabling identification of target pairs that further enhance therapeutic index
